BioAdaptives, Inc. (OTC: BDPT) has announced the upcoming commercial launch of XcellaraHeart™, a cardiovascular wellness supplement that combines the company's Xcellara™ stem/progenitor cell mobilization formula with Tanshinone IIA, a bioactive compound derived from Danshen root. The product is scheduled to be available for order beginning Aug. 1, 2026, with initial deliveries expected in early August.
The company stated that the Xcellara™ base is supported by a randomized, double-blind, placebo-controlled clinical trial that demonstrated an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks. Tanshinone IIA has been studied for its effects on the SDF-1α/CXCR4 signaling pathway, which is associated with cellular trafficking and cardiovascular repair biology. The product is designed around a two-part cardiovascular wellness strategy combining stem/progenitor cell mobilization with cardiovascular signaling support.
BioAdaptives noted that a scientific evidence dossier detailing the formulation is available on the company's product website at products.xcellara.com/science. The dossier separates what has been demonstrated in BioAdaptives' human clinical research on the Xcellara™ base from published research on Tanshinone IIA and from the company's product-development rationale for combining the two.
The Xcellara™ base formula is the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks with zero adverse effects on more than twenty blood parameters. The Xcellara product line includes seven targeted formulas combining the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications.
For more information about BioAdaptives, visit www.bioadaptives.com. The full press release is available at https://nnw.fm/G14S7.
